NEW YORK, NY / ACCESSWIRE / February 3, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/srpt.
The investigation concerns whether Sarepta and certain of its officers and/or directors have violated federal securities laws.
On January 7, 2021, Sarepta revealed that its one-time gene therapy for Duchenne muscular dystrophy did not show benefits compared to a placebo. Following this news, Sarepta stock dropped roughly 49.7%, during after-market trading, and opened at $85.00 on January 8, 2021.
If you are aware of any facts relating to this investigation, or purchased Sarepta shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/srpt. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC